Kaiser Permanente Medical Care Program California Division – South SCPMG Laboratory Systems Coagulation Process

APTT Mixing Study


Introduction	This process describes the stages that comprise the APTT mixing study workflow.		
Scope	The intended users of this document include Clinical Laboratory Scientists (CLS) and Laboratory Technical Supervisors handling APTT mixing study samples, issues, or concerns.		
Process	Refer to the diagram on Page 2 of this document to view the APTT mixing study workflow.		
	Continued on next page		

Document No.: COAG.SCPMG.001

Version No.: 02

Examination Procedures Page 1 of 5

APTT Mixing Study, Continued



Report Comment Interpretations

- APTT Norm: Patient baseline APTT is normal. Mixing Study not performed.
- APTT Min Prolon: Patient baseline APTT is minimally prolonged (<5 seconds). Mixing study not performed due to limited clinical
 utility in these cases.
- APTT Remains Correct: APTT corrects with immediate mixing and remains corrected with incubation. Results of these studies are suggestive of factor deficiency.
- Does Not Remain: APTT corrects with immediate mixing, but does not remain corrected with incubation. Results of these studies
 indicate a time- or temperature-dependent factor inhibitor such as factor VIII inhibitor or some lupus anti-coagulants. Further
 studies such as Factor VIII inhibitor or lupus anticoagulant testing may help identify the specific inhibitor.
- Does Not Correc: APTT does not correct with mixing. Results are suggestive of an inhibitor. The presence of anticoagulant inhibitor drugs such as heparin or direct thrombin inhibitors cannot be excluded.

Continued on next page

Document No.: COAG.SCPMG.001

Version No.: 02

Kaiser Permanente Medical Care Program California Division – South

SCPMG Laboratory Systems
Coagulation
Process

APTT Mixing Study, Continued

Non-Controlled Documents

The following non-controlled document supports this policy.

Clinical and Laboratory Standards Institute (CLSI). Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline-Fifth Edition. CLSI document H21-A5 (ISBN 1-56238-657-3). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2008.

Controlled Documents

The following controlled document supports this procedure.

	Procedure	
APTT Mixing Study		

Author(s)

Ji Yeon Kim, MD, MPH Bill Brice, MT(ASCP), MBA

Eleanor E. Callasan, MPH, CLS(ASCP)

Document No.: COAG.SCPMG.001

Version No.: 02

Examination Procedures Page 3 of 5

APTT Mixing Study, Continued

Reviewed and approved by:

Signature	Date
may alel	11/24/2013
Mary Anne Umekubo, MS, CLS	
Assistant Director of Laboratory Services, Esoteric Chemistry &	0
Special Coagulation	
FDiz	11/21/2013
Vincent Dizon, MBA, CLS	
Director of Laboratory Services, Chemistry Section	
moureen ahler	11/21/2013
Maureen Ahler, MSQA, MT(ASCP)	
SCPMG Quality Systems Leader	
Jyk.	11/21/13
Ji Yeon Kim, MD, MPH	
Physidian-in-Charge, Clinical Chemistry & Laboratory Informatics	
11),40,00	11/22/13
Darryl Erik Palmer-Toy, MD, PhD	
Assistant Medical Director of Laboratory Services, SCPMG	
Medical Director, SCPMG Regional Reference Laboratories	
Chair - Laboratory Quality Operations	

Reviewed and approved by (for Medical Center Area Approval Only):

SIGNATURE	DATE	
Name:		
Operations Director, Area Laboratory		
Name:		
CLIA Laboratory Director		

Continued on next page

Document No.: COAG.SCPMG.001	Examination Procedures	
Version No.: 02	Page 4 of 5	